It seems that the VNP platform used herein can successfully break tolerance to self proteins such as IL-12 after repeated i.m. application, which may be useful in future studies aimed at blunting undesired cytokines response, e.g., high IL-4, IL-5 and/or IL-13 levels as observed in allergic diseases. The gene discussed is IL13; the disease is allergic disease.